Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
- 3 February 2012
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 13 (4), 585-591
- https://doi.org/10.1517/14656566.2012.658368
Abstract
Introduction: Age-related macular degeneration (AMD) continues to be a leading cause of blindness worldwide. The neovascular form of the disease can lead to rapid and progressive vision loss. Vascular endothelial growth factor (VEGF) has emerged as a key target of treatment, with inhibitors of VEGF being shown to arrest the angiogenic process and avoid the visual damage typically associated with its presence. Areas covered: This manuscript reviews the treatment history for wet AMD and examines aflibercept, a new, fully human, recombinant fusion protein designed to bind all isoforms of VEGF-A, as well as placental growth factor (PGF), thereby inhibiting the binding and activation of VEGF receptors. Expert opinion: The results of Phase I, II and III studies have proven aflibercept to be a safe and effective treatment for wet AMD. Recent results of Phase III studies demonstrate the efficacy of aflibercept, dosed every 8 weeks after three initial monthly doses, and show that this regimen is clinically equivalent to monthly ranibizumab therapy. Eylea™ (aflibercept) was approved by the FDA for the treatment of wet AMD on 18 November 2011.Keywords
This publication has 35 references indexed in Scilit:
- The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed DosingOphthalmology, 2011
- Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular DegenerationOphthalmology, 2011
- Drug delivery strategies for therapeutic angiogenesis and antiangiogenesisExpert Opinion on Drug Delivery, 2011
- VEGF Trap-Eye for the treatment of neovascular age-related macular degenerationExpert Opinion on Investigational Drugs, 2009
- Predicted biological activity of intravitreal VEGF TrapBritish Journal of Ophthalmology, 2008
- Targeting Vascular Endothelial Growth FactorDrugs & Aging, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006
- Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A reviewClinical Therapeutics, 2006
- VERTEPORFIN THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2004